Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Humira 40 mg solution for injection in pre-filled syringe, ORENCIA 50 mg solution for injection in pre-filled syringe, Tyenne 162mg/0.9ml solution for injection in pre-filled syringe, Humira 20 mg solution for injection in pre-filled syringe, XELJANZ 1 mg/mL oral solution, Enbrel 50 mg solution for injection in pre-filled syringe, Enbrel 25 mg solution for injection in pre-filled syringe, ORENCIA 125 mg solution for injection in pre-filled syringe, XELJANZ 5 mg film-coated tablets, ORENCIA 87.5 mg solution
The George Institute
Juvenile Idiopathic Arthritis
1 trial -
ORENCIA 250 mg powder for concentrate for solution for infusion, METHOTREXATE/PFIZER, ORENCIA 250 mg powder for concentrate for solution for infusion, ORENCIA 250 mg powder for concentrate for solution for infusion, DRL_AB
Dr Reddy''s Laboratories (Australia) Pty Ltd
Rheumatoid Arthritis
1 trial -
Humira 40 mg solution for injection in pre-filled pen, ORENCIA 125 mg solution for injection in pre-filled syringe, Enbrel 50 mg solution for injection in pre-filled syringe, Reumaflex 50 mg/ml soluzione iniettabile, siringa preriempita, ORENCIA 250 mg powder for concentrate for solution for infusion, Cosentyx 150 mg solution for injection in pre-filled syringe, Enbrel 25 mg solution for injection in pre-filled syringe, Simponi 45 mg/0.45 mL solution for injection in pre-filled pen., Jylamvo 2 mg/ml oral so
Istituto Gentili S.r.l.
Juvenile idiopathic arthritis
1 trial -
ORENCIA 125 mg solution for injection in pre-filled syringe, ORENCIA 125 mg solution for injection in pre-filled syringe, RoActemra 162 mg solution for injection in pre-filled syringe., ORENCIA 125 mg solution for injection in pre-filled syringe, ORENCIA 125 mg solution for injection in pre-filled syringe, RoActemra 162 mg solution for injection in pre-filled syringe., ORENCIA 125 mg solution for injection in pre-filled syringe, ORENCIA 125 mg solution for injection in pre-filled syringe, ORENCIA 125 mg sol
The George Institute
Adults patients suffering from rheumatoid arthritis and in adequate response to one or two targeted treatments.
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources